For instance, in patients with NSCLC treated with pembrolizumab, higher non-synonymous mutation burden in tumors was found to be associated with improved objective response, durable clinical benefit, progression-free survival, and neoantigen-specific CD8+ T cell responses paralleled tumor regression [96]. Here, CD8A is linked to neoplasm.